文献速递泌尿男性生殖肿瘤

PI3激酶抑制剂布帕利塞联合或不联合恩扎卢胺治疗转移性去势抵抗性前列腺癌男性的II期试验

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
PubMed 文献 · Eur J Cancer · 2017-05-11

这项多中心单臂II期试验评估布帕利塞100mg±恩扎卢胺每日治疗多西他赛进展或不适合多西他赛的mCRPC男性,主要终点为6个月影像学/临床无进展生存率。30例患者中6个月PFS率为10%(95%CI 2.5-23.6%),中位PFS 1.9个月,联合恩扎卢胺时中位PFS 3.5个月,中位OS 10.6个月。结论认为布帕利塞未显示显著活性。

要点

  • 30例mCRPC患者中6个月PFS率为10%(95%CI 2.5-23.6%),中位PFS 1.9个月。
  • 联合恩扎卢胺时中位PFS为3.5个月,但恩扎卢胺使布帕利塞浓度降低五倍。
  • 23%患者出现PSA下降,但无人PSA下降≥50%,无影像学缓解。

核心结论

  • 布帕利塞在mCRPC男性中未显示显著活性,提示PI3K抑制不足以逆转耐药性mCRPC进展。
  • 未来PI3K通路抑制剂联合恩扎卢胺的研究应确定最佳剂量并聚焦于更可能获益的选定患者。

研究设计与样本

  • 多中心单臂II期试验,布帕利塞100mg±恩扎卢胺每日给药。
  • 纳入多西他赛进展或不适合多西他赛的mCRPC男性,主要终点为6个月影像学/临床无进展生存率。
  • 共入组30例患者。

主要发现

  • 67%为多西他赛后,中位PSA为70 ng/dl,83%曾接受≥4种mCRPC治疗,43%同时接受恩扎卢胺。
  • 6个月PFS率估计为10%(95%CI 2.5-23.6%),中位PFS为1.9个月,联合恩扎卢胺时中位PFS为3.5个月,中位OS为10.6个月。
  • 同时使用恩扎卢胺导致布帕利塞浓度降低五倍。
  • 23%患者出现PSA下降,无患者达到≥50%下降,未观察到影像学缓解。
  • 4例发生严重不良事件,包括呼吸道感染和多器官衰竭、尿路梗阻、意识模糊及新发中枢神经系统转移情况下的1次癫痫发作;43%患者出现III级不良事件。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为未来PI3K通路抑制剂联合恩扎卢胺的研究应确定最佳剂量并聚焦于更可能获益的选定患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Phosphatidylinositol-3-kinase (PI3K) and androgen receptor pathway activation is common in metastatic castration resistant prostate cancer (mCRPC). Buparlisib is an oral, pan-class I PI3 kinase inhibitor. METHODS: This was a multisite single arm phase II trial of buparlisib 100 mg ± enzalutamide daily in men with mCRPC whose disease progressed on or who were not candidates for docetaxel. The primary end-point was the rate of radiographic/clinical progression-free survival (PFS) at 6 months. RESULTS: Thirty men were accrued: 67% post-docetaxel; median prostate specific antigen (PSA) was 70 ng/dl, 83% had ≥4 prior therapies for mCRPC; 43% received concurrent enzalutamide. The final 6 month PFS rate was estimated to be 10% (95% confidence interval 2.5-23.6%). Median PFS was 1.9 months and was 3.5 months with concurrent enzalutamide. Median overall survival was 10.6 months. Concurrent enzalutamide led to a five-fold reduction in buparlisib concentrations. PSA declines were observed in 23%; no patients achieved a ≥50% decline, and no radiographic responses were observed. Severe adverse events occurred in four men including respiratory infection and multi-organ failure, urinary tract obstruction, confusion and one seizure in the setting of a new central nervous system (CNS) metastasis. Grade III adverse events were seen in 43% of patients; common toxicities included grade I-II weight loss, diarrhoea, nausea, fatigue, anorexia, rash, hyperglycemia and anxiety/mood disorders. CONCLUSIONS: Buparlisib did not demonstrate significant activity in men with mCRPC, suggesting that PI3K inhibition is not sufficient to reverse resistant mCRPC progression. Future studies of PI3K pathway inhibitors with concurrent enzalutamide should develop optimal dosing and focus on selected patients more likely to benefit.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Armstrong AJ, Halabi S, Healy P, et al. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. Eur J Cancer. 2017. PMID: 28502694. doi:10.1016/j.ejca.2017.02.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。